These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 26389942)

  • 1. Optimization of a siRNA Carrier Modified with a pH-Sensitive Cationic Lipid and a Cyclic RGD Peptide for Efficiently Targeting Tumor Endothelial Cells.
    Hada T; Sakurai Y; Harashima H
    Pharmaceutics; 2015 Sep; 7(3):320-33. PubMed ID: 26389942
    [TBL] [Abstract][Full Text] [Related]  

  • 2. RNAi-mediated gene knockdown and anti-angiogenic therapy of RCCs using a cyclic RGD-modified liposomal-siRNA system.
    Sakurai Y; Hatakeyama H; Sato Y; Hyodo M; Akita H; Ohga N; Hida K; Harashima H
    J Control Release; 2014 Jan; 173():110-8. PubMed ID: 24120854
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Failure of active targeting by a cholesterol-anchored ligand and improvement by altering the lipid composition to prevent ligand desorption.
    Yamamoto S; Sakurai Y; Harashima H
    Int J Pharm; 2018 Jan; 536(1):42-49. PubMed ID: 29126905
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel antiangiogenic therapy targeting biglycan using tumor endothelial cell-specific liposomal siRNA delivery system.
    Maishi N; Sakurai Y; Hatakeyama H; Umeyama Y; Nakamura T; Endo R; Alam MT; Li C; Annan DA; Kikuchi H; Morimoto H; Morimoto M; Akiyama K; Ohga N; Hida Y; Harashima H; Hida K
    Cancer Sci; 2022 May; 113(5):1855-1867. PubMed ID: 35266253
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Development of siRNA Delivery Targeting the Tumor Microenvironment with a New Functional Device].
    Sakurai Y
    Yakugaku Zasshi; 2019; 139(11):1357-1363. PubMed ID: 31685731
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preparation of a Cyclic RGD: Modified Liposomal SiRNA Formulation for Use in Active Targeting to Tumor and Tumor Endothelial Cells.
    Sakurai Y; Hada T; Harashima H
    Methods Mol Biol; 2016; 1364():63-9. PubMed ID: 26472442
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficient siRNA Delivery by Lipid Nanoparticles Modified with a Nonstandard Macrocyclic Peptide for EpCAM-Targeting.
    Sakurai Y; Mizumura W; Murata M; Hada T; Yamamoto S; Ito K; Iwasaki K; Katoh T; Goto Y; Takagi A; Kohara M; Suga H; Harashima H
    Mol Pharm; 2017 Oct; 14(10):3290-3298. PubMed ID: 28789523
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Development of an efficient short interference RNA (siRNA) delivery system with a new pH-sensitive cationic lipid].
    Sato Y; Hatakeyama H; Hyodo M; Akita H; Harashima H
    Yakugaku Zasshi; 2012; 132(12):1355-63. PubMed ID: 23208041
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Endosomal escape and the knockdown efficiency of liposomal-siRNA by the fusogenic peptide shGALA.
    Sakurai Y; Hatakeyama H; Sato Y; Akita H; Takayama K; Kobayashi S; Futaki S; Harashima H
    Biomaterials; 2011 Aug; 32(24):5733-42. PubMed ID: 21605898
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Construction and Biological Evaluation of a Novel Integrin α
    Chen X; Liu M; Wang R; Yan P; Zhang C; Ma C; Yin L
    Molecules; 2017 Feb; 22(2):. PubMed ID: 28165399
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Silencing of VEGFR2 by RGD-Modified Lipid Nanoparticles Enhanced the Efficacy of Anti-PD-1 Antibody by Accelerating Vascular Normalization and Infiltration of T Cells in Tumors.
    Cho R; Sakurai Y; Jones HS; Akita H; Hisaka A; Hatakeyama H
    Cancers (Basel); 2020 Dec; 12(12):. PubMed ID: 33291555
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeted delivery of small interfering RNA to angiogenic endothelial cells with liposome-polycation-DNA particles.
    Vader P; Crielaard BJ; van Dommelen SM; van der Meel R; Storm G; Schiffelers RM
    J Control Release; 2012 Jun; 160(2):211-6. PubMed ID: 21983283
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A pH-sensitive cationic lipid facilitates the delivery of liposomal siRNA and gene silencing activity in vitro and in vivo.
    Sato Y; Hatakeyama H; Sakurai Y; Hyodo M; Akita H; Harashima H
    J Control Release; 2012 Nov; 163(3):267-76. PubMed ID: 23000694
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeted systemic delivery of siRNA to cervical cancer model using cyclic RGD-installed unimer polyion complex-assembled gold nanoparticles.
    Yi Y; Kim HJ; Mi P; Zheng M; Takemoto H; Toh K; Kim BS; Hayashi K; Naito M; Matsumoto Y; Miyata K; Kataoka K
    J Control Release; 2016 Dec; 244(Pt B):247-256. PubMed ID: 27590214
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeted anti-cancer therapy: Co-delivery of VEGF siRNA and Phenethyl isothiocyanate (PEITC) via cRGD-modified lipid nanoparticles for enhanced anti-angiogenic efficacy.
    Li B; Niu H; Zhao X; Huang X; Ding Y; Dang K; Yang T; Chen Y; Ma J; Liu X; Zhang K; Xie H; Ding P
    Asian J Pharm Sci; 2024 Apr; 19(2):100891. PubMed ID: 38584690
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Functional improvement of an IRQ-PEG-MEND for delivering genes to the lung.
    Ishitsuka T; Akita H; Harashima H
    J Control Release; 2011 Aug; 154(1):77-83. PubMed ID: 21619903
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effective Therapy Using a Liposomal siRNA that Targets the Tumor Vasculature in a Model Murine Breast Cancer with Lung Metastasis.
    Sakurai Y; Hada T; Kato A; Hagino Y; Mizumura W; Harashima H
    Mol Ther Oncolytics; 2018 Dec; 11():102-108. PubMed ID: 30534584
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sequential treatment of drug-resistant tumors with RGD-modified liposomes containing siRNA or doxorubicin.
    Jiang J; Yang SJ; Wang JC; Yang LJ; Xu ZZ; Yang T; Liu XY; Zhang Q
    Eur J Pharm Biopharm; 2010 Oct; 76(2):170-8. PubMed ID: 20600887
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Polycondensed Peptide-Based Polymers for Targeted Delivery of Anti-Angiogenic siRNA to Treat Endometriosis.
    Egorova A; Maretina M; Krylova I; Kiselev A
    Int J Mol Sci; 2023 Dec; 25(1):. PubMed ID: 38203184
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reducing the Cytotoxicity of Lipid Nanoparticles Associated with a Fusogenic Cationic Lipid in a Natural Killer Cell Line by Introducing a Polycation-Based siRNA Core.
    Nakamura T; Yamada K; Fujiwara Y; Sato Y; Harashima H
    Mol Pharm; 2018 Jun; 15(6):2142-2150. PubMed ID: 29668291
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.